Friday morning brought mixed signals to the market, with Dow futures slipping around 0.1% while several notable stocks faced pre-market pressure.

The Big Decliner: Biohaven's Depression Drug Setback

Biohaven Ltd (BHVN) took the hardest hit, plummeting after disappointing Phase 2 trial results for its depression treatment. The biopharmaceutical company revealed that BHV-7000, an investigational drug designed to treat major depressive disorder, failed to achieve a statistically significant reduction in depressive symptoms compared to placebo. The six-week study measured results using the Montgomery Åsberg Depression Rating Scale, a standard tool for assessing depression severity.

The news sent Biohaven shares tumbling 14.3% to $9.27 in pre-market action.

Other Notable Decliners

Heartland Express Inc (HTLD) dropped 8.9% to $8.40 in pre-market trading, despite the trucking company recently announcing a regular quarterly cash dividend of 2 cents per share. Sometimes good news isn't enough to overcome broader market sentiment.

Omeros Corp (OMER) declined 6.8% to $14.32 in pre-market trading. The biotech had jumped over 75% on Wednesday following FDA approval of YARTEMLEA for treating hematopoietic stem cell transplant-associated thrombotic microangiopathy. Friday's pullback appears to be some natural profit-taking after that explosive rally.

Andersen Group Inc (ANDG) fell 4.6% to $24.30 in pre-market trading after posting a 4% gain on Wednesday.

Several other stocks saw modest declines. PennyMac Mortgage Investment Trust (PMT) dropped 2.8% to $12.67, while Black Rock Coffee Bar Inc (BRCB) slipped 2.7% to $22.70. Lifestance Health Group Inc (LFST) fell 2.7% to $6.90, and Kyverna Therapeutics Inc (KYTX) declined 2.6% to $8.76 in pre-market action.